DESTINY-Breast03 Phase 3 Study Results
Daiichi-Sankyo
Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer
patients with active brain metastases: Primary outcome analysis from
the TUXEDO-1 trial
Rupert Bartsch¹, Anna Sophie Berghoff 1, Julia Furtner 2, Maximilian Marhold 1, Elisabeth Sophie Bergen 1, Sophie
Roider-Schur ³, Angelika Martina Starzer 1, Heidrun Forstner 1, Beate Rottenmanner 1, Karin Dieckmann 4, Zsuzsanna
Bago-Horvath 5, Georg Widhalm 6, Aysegül Ilhan-Mutlu 1, Christoph Minichsdorfer 1, Thorsten Fuereder 1, Christian
Singer 7, Ansgar Weltermann 8, Rainer Puhr 1, Matthias Preusser 1
3
1 Department of Medicine 1, Division of Oncology, Medical University of Vienna; 2 Department of Radiology, Medical University of Vienna, Vienna,
Austria; ³ Department Oncology, St. Joseph's Hospital, Vienna, Austria; 4 Department of Radio-Oncology, Medical University of Vienna, Vienna, Austria;
5 Department of Pathology, Medical University of Vienna, Vienna, Austria; 6 Department of Neurosurgery, Medical University of Vienna, Vienna,
Austria; 7 Department of Gynaecology, Medical University of Vienna, Vienna, Austria; 8 Department of Medicine 1, Elisabethinen Hospital Linz,
Ordensklinkum Linz, Linz, Austria
Investigator-Initiated Study
ESMO BC 2022 #165 Mini Oral
On behalf of the investigators
50
50View entire presentation